Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5483
Abstract: The phase 3 CLEAR study demonstrated statistically significantly improved efficacy with lenvatinib plus pembrolizumab versus sunitinib, including progression‐free survival and overall survival, in patients with previously untreated advanced renal cell carcinoma. This subset analysis investigated… read more here.
Keywords: sunitinib; plus pembrolizumab; pembrolizumab versus; lenvatinib plus ... See more keywords
Effectiveness and safety of lenvatinib plus anti‐programmed death‐1 antibodies in patients with hepatocellular carcinoma: A real‐world cohort study
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5661
Abstract: Lenvatinib plus anti‐programmed death‐1 (anti‐PD‐1) antibody combinations have shown potent anti‐tumor effect in phase I/II trials in advanced or unresectable hepatocellular carcinoma (HCC), but real‐world data are limited. read more here.
Keywords: hepatocellular carcinoma; plus anti; programmed death; anti programmed ... See more keywords
The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy.
Sign Up to like & getrecommendations! Published in 2020 at "Clinical genitourinary cancer"
DOI: 10.1016/j.clgc.2020.03.003
Abstract: BACKGROUND Patients with primary refractory metastatic renal cell carcinoma (mRCC) have a dismal prognosis and poor response to subsequent treatments. While there are several approved second-line therapies, it remains critical to choose the most effective… read more here.
Keywords: lenvatinib plus; line; plus everolimus; primary resistance ... See more keywords
A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma.
Sign Up to like & getrecommendations! Published in 2021 at "European urology"
DOI: 10.1016/j.eururo.2021.03.015
Abstract: BACKGROUND Non-clear cell renal cell carcinoma (nccRCC) accounts for ≤20% of RCC cases. Lenvatinib (a multitargeted tyrosine kinase inhibitor) in combination with everolimus (an mTOR inhibitor) is approved for the treatment of advanced RCC after… read more here.
Keywords: lenvatinib plus; plus everolimus; study; single arm ... See more keywords
Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study
Sign Up to like & getrecommendations! Published in 2022 at "Liver Cancer"
DOI: 10.1159/000523849
Abstract: Introduction: Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma (HCC). We aimed to compare the clinical outcomes of lenvatinib plus drug-eluting beads transarterial chemoembolization (DEB-TACE) versus lenvatinib alone in real-world practice. Methods: This retrospective… read more here.
Keywords: hepatocellular carcinoma; drug eluting; lenvatinib; advanced hepatocellular ... See more keywords
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.00221
Abstract: PURPOSE Effective treatments are needed for melanoma that progresses on inhibitors of programmed cell death protein-1 (PD-1) or its ligand (PD-L1). We conducted the phase II LEAP-004 study to evaluate the combination of the multikinase… read more here.
Keywords: plus pembrolizumab; inhibitor; death; melanoma confirmed ... See more keywords
Feasibility and Tolerability of Lenvatinib, Plus PD-1 Blockades for Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Management and Research"
DOI: 10.2147/cmar.s372125
Abstract: Objective Lenvatinib was the standard first-line therapy for patients with unresectable HCC. PD-1 blockades demonstrated promising efficacy for patients with previously-treated HCC. Therefore, this study was to investigate the feasibility and tolerability of lenvatinib plus… read more here.
Keywords: patients unresectable; plus blockades; lenvatinib plus; response ... See more keywords
Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2023.1141199
Abstract: Background Lenvatinib monotherapy and combination therapy with immune checkpoint inhibitors (ICI) were widely applied for unresectable hepatocellular carcinoma (uHCC). However, many patients failed to benefit from the treatments. A prognostic model was needed to predict… read more here.
Keywords: lenvatinib monotherapy; model; lenvatinib plus; treatment ... See more keywords
Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.980214
Abstract: Lenvatinib plus transarterial chemoembolization (TACE)have become the first choice for patients with hepatocellular carcinoma (HCC) that are unsuitable for TACE. Sorafenib plus TACE therapy for patients with portal vein tumor thrombus (PVTT) achieved positive results.… read more here.
Keywords: plus transarterial; therapy; lenvatinib plus; transarterial chemoembolization ... See more keywords